• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry.
CONCLUSIONS: In current practice, cardiovascular events occurring under TCZ treatment is in the range of what is expected in RA patients despite a global increase in cholesterol levels. PMID: 32896267 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - September 12, 2020 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA. PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
ConclusionHigher IRs of AESI were observed in patients with GCA versus those with RA in both TCZ-na ïve and -treated cohorts. Differences in underlying disease, age, and glucocorticoid use may influence AESI incidence, irrespective of intervention.FundingThis study was funded by F. Hoffmann-La Roche Ltd and Genentech, Inc. Article processing charges were funded by F. Hoffmann-La Roche Ltd.Plain Language SummaryPlain language summary is available for this article.
Source: Rheumatology and Therapy - February 1, 2019 Category: Rheumatology Source Type: research

Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept.
CONCLUSIONS: RA patients with TCZ do not have a medium-term excess of CV risk in patients compared with ETN. PMID: 29303702 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - January 6, 2018 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

Cardiovascular Safety of Tocilizumab versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis – a Multi‐database Cohort Study
Conclusion: This multi‐database population‐based cohort study found no evidence of an increased CV risk among RA patients who switched from a different biologic drug or tofacitinib to TCZ versus to a TNFi. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - February 27, 2017 Category: Rheumatology Authors: Seoyoung C. Kim, Daniel H. Solomon, James R. Rogers, Sara Gale, Micki Klearman, Khaled Sarsour, Sebastian Schneeweiss Tags: Full Length Source Type: research